Status:
COMPLETED
Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
Lead Sponsor:
Marmara University
Conditions:
Axial Spondyloarthritis
Central Sensitisation
Eligibility:
All Genders
18-65 years
Brief Summary
The term axial spondyloarthritis (axSpA) describes a group of chronic inflammatory diseases that characterized with spinal involvement. AxSpA is one of the most common rheumatic diseases and chronic p...
Detailed Description
The term axial spondyloarthritis (axSpA) describes a group of chronic inflammatory diseases that characterized with spinal involvement. AxSpA is one of the most common rheumatic diseases and chronic p...
Eligibility Criteria
Inclusion
- Diagnosed with axSpA according to the Assessment of SpondyloArthritis International Society (ASAS) criteria Aged between 18-65 years
Exclusion
- Had an other rheumatic diseases, peripheral vascular disease, peripheral neuropathy and spine disease (e.g., symptomatic herniated disc, spinal stenosis), Using centrally acting pain medications (e.g., pregabaline, duloxetine, opioids) or glucocorticoids (\>10 mg prednisone or its equivalent) within 3 months of study enrollment
- The exclusion criteria of the control grup were same as that of the patients.
Key Trial Info
Start Date :
October 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 18 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04485078
Start Date
October 20 2019
End Date
April 18 2020
Last Update
August 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Feyza Nur YUCEL
Istanbul, Turkey (Türkiye), 34100